SAN FRANCISCO, CA – (February 6, 2025) – National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Novo Nordisk A/S. (“Novo” or the “Company”) (NYSE: NVO) who purchased or otherwise acquired Novo securities between November 2, 2022, and December 19, 2024, inclusive (the “Class Period”) to contact us immediately regarding a